title: Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis.
abstract: BACKGROUND
  Serum alpha-L-fucosidase activity is considered a marker of hepatocellular carcinoma. To the authors' knowledge, its clinical usefulness in the early detection of hepatocellular carcinoma in the follow-up of cirrhotic patients has not been reported previously.
  
  
  METHODS
  The authors prospectively studied serum alpha-L-fucosidase activity, in addition to alpha-fetoprotein and ultrasonography, in a regular screening of 132 cirrhotic patients during an 8-year follow-up.
  
  
  RESULTS
  At enrollment, 120 patients had low alpha-L-fucosidase activity (below the cutoff value) and 12 had high activity. All patients had serum alpha-fetoprotein levels below the cutoff value. During the follow-up, hepatocellular carcinoma was detected in 19 patients, 16 with alpha-L-fucosidase activity below the cutoff value at enrollment and 3 with activity above it. In 7 of those 16 patients with carcinoma and low enzyme activity, the enzyme activity showed a significant increase 6-9 months before there was ultrasonographic evidence of a focal lesion, and by the time of diagnosis it had risen above the cutoff value in all of them; in only 3 of the 7 patients was the increase in alpha-L-fucosidase activity associated with an increase in alpha-fetoprotein. In another 4 of the 19 patients with carcinoma, only alpha-fetoprotein increased.
  
  
  CONCLUSIONS
  Serum alpha-L-fucosidase activity is useful in the early detection of hepatocellular carcinoma. The data from this study suggest that cirrhotic patients who have a marked increase in serum alpha-L-fucosidase levels during follow-up should be closely monitored for signs of hepatocellular carcinoma development.
authors.affiliation: Department of Internal Medicine, University of Naples Federico II, Italy.
authors.forename: M G
authors.initials: MG
authors.lastname: Giardina
authors.forename: M
authors.initials: M
authors.lastname: Matarazzo
authors.forename: R
authors.initials: R
authors.lastname: Morante
authors.forename: A
authors.initials: A
authors.lastname: Lucariello
authors.forename: A
authors.initials: A
authors.lastname: Varriale
authors.forename: V
authors.initials: V
authors.lastname: Guardasole
authors.forename: G
authors.initials: G
authors.lastname: De Marco
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000000981:diagnostic imaging; D004796:Clinical Enzyme Tests; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008103:Liver Cirrhosis / Q000201:enzymology*; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014463:Ultrasonography; D000509:alpha-Fetoproteins / Q000032:analysis; D005644:alpha-L-Fucosidase / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D000509:alpha-Fetoproteins; D005644:alpha-L-Fucosidase